Neumora Therapeutics (NMRA) Projected to Post Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA) is expected to be posting its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Neumora Therapeutics Price Performance

Shares of NMRA opened at $3.39 on Monday. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $3.65. The firm’s 50-day simple moving average is $2.20 and its two-hundred day simple moving average is $2.08. The stock has a market cap of $566.44 million, a PE ratio of -2.31 and a beta of 3.20. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on NMRA shares. Guggenheim upgraded Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a report on Monday, October 27th. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $4.00 to $7.00 in a research report on Monday, December 1st. Mizuho set a $6.00 price objective on shares of Neumora Therapeutics in a research note on Monday, January 5th. Leerink Partners began coverage on shares of Neumora Therapeutics in a research note on Monday, January 12th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Neumora Therapeutics has a consensus rating of “Hold” and an average target price of $8.13.

Insider Activity

In other news, insider Paul L. Berns sold 9,819 shares of Neumora Therapeutics stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the completion of the sale, the insider directly owned 7,395,185 shares in the company, valued at $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 23,387 shares of company stock worth $82,647. Company insiders own 26.80% of the company’s stock.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in Neumora Therapeutics during the 3rd quarter valued at $31,000. Fred Alger Management LLC bought a new stake in shares of Neumora Therapeutics in the fourth quarter worth $40,000. Canada Pension Plan Investment Board purchased a new stake in Neumora Therapeutics during the second quarter valued at $41,000. Public Employees Retirement System of Ohio purchased a new stake in Neumora Therapeutics during the third quarter valued at $44,000. Finally, Barclays PLC lifted its holdings in Neumora Therapeutics by 202.0% in the fourth quarter. Barclays PLC now owns 30,924 shares of the company’s stock valued at $55,000 after acquiring an additional 20,683 shares during the period. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Trending Headlines about Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: William Blair upgraded NMRA from Market Perform to Outperform, a catalyst that helped lift shares and drew investor attention. Neumora Therapeutics (NASDAQ:NMRA) Stock Rating Upgraded by William Blair
• Positive Sentiment: Other broker research has become more bullish in recent months (Needham, RBC, Mizuho), with several firms raising price targets — a supportive backdrop for shares and longer‑term sentiment. MarketBeat: Neumora Therapeutics coverage and analyst notes
• Neutral Sentiment: Institutional ownership is meaningful (~47.7%); a mix of hedge funds/institutions recently took or adjusted positions, which can amplify moves but doesn’t signal a directional near‑term catalyst by itself. MarketBeat: Hedge funds and institutional ownership
• Neutral Sentiment: Company profile: Neumora is a clinical‑stage CNS biotech with an R&D pipeline across small molecules, biologics and gene modalities — typical risk/reward profile for a clinical-stage drug developer. MarketBeat: About Neumora Therapeutics
• Negative Sentiment: Multiple insiders sold shares on Feb. 17 (President Joshua Pinto: 5,967 shares; Paul L. Berns: 9,819; Daljit Singh Aurora: 6,165; Michael Lee Milligan: 1,436) — roughly ~23k shares disclosed — which can create downward pressure and signal near‑term caution to investors. Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) President Sells 5,967 Shares of Stock

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.